Professor, Departments of Radiation Oncology, Neurological Surgery, and Pathology
My lab is focused on understanding genomic, biochemical, and cellular drivers of brain tumor heterogeneity and evolution. To do so, my lab integrates human samples with evolutionarily-diverse preclinical models to understand brain tumor biology and develop new biomarkers and new treatments for patients. Using DNA methylation profiling on 565 human samples and genetic, transcriptomic, biochemical, proteomic, single-cell, mechanistic, and functional approaches in organoids and mice, we identified molecular groups of brain tumors with distinct clinical outcomes, biological drivers, and therapeutic vulnerabilities. Building on these foundational data, we performed 4898 bioinformatic assays on 1856 tumors from 12 medical centers across 3 continents to develop a targeted gene expression biomarker that improves prediction of clinical outcomes.
